This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Postpartum haemorrhage

Authoring team

This is bleeding from the genital tract after the delivery of a baby.

It can be broadly divided into primary and secondary types, the distinction being the timing of the onset of the bleed relative to the delivery (1,2).

A primary postpartum haemorrhage is a loss (usually defined as more than 500ml) in the first 24 hours after delivery.

It is important to note that in pregnancy the clinical parameters may be unreliable; for example, apparent normotension can be due to pre-eclampsia combined with blood loss.

Postpartum bleeding - Postnatal Care (3)

Discuss with women what vaginal bleeding to expect after the birth (lochia), and advise women to seek medical advice if:

  • the vaginal bleeding is sudden or very heavy
  • the bleeding increases
  • they pass clots, placental tissue or membranes
  • they have symptoms of possible infection, such as abdominal, pelvic or perineal pain, fever, shivering, or vaginal bleeding or discharge has an unpleasant smell
  • they have concerns about vaginal bleeding after the birth

If a women seeks medical advice about vaginal bleeding after the birth, assess the severity, and be aware of the risk factors for postpartum haemorrhage

  • Antenatal risk factors:
  • previous retained placenta or postpartum haemorrhage
  • maternal haemoglobin level below 85 g/litre at onset of labour
  • BMI greater than 35 kg/m2
  • grand multiparity (parity4 or more)
  • antepartum haemorrhage
  • overdistention of the uterus (for example, multiple pregnancy, polyhydramnios or macrosomia)
  • existing uterine abnormalities
  • low-lying placenta
  • maternal age of 35 years or older.
  • Risk factors in labour:
  • induction
  • prolonged first, second or third stage of labour
  • oxytocin use
  • precipitate labour
  • operative birth or caesarean section

Also be aware of the following factors, which may worsen the consequences of secondary postpartum haemorrhage:

  • anaemia
  • weight of less than 50 kg at the first appointment with the midwife during pregnancy (booking appointment).

Prevention of postpartum haemorrhage (2):

  • traditionally, oxytocin and ergot preparations have been used as uterotonic agents for postpartum haemorrhage prophylaxis mostly as part of active management of the third stage of labour
    • a major disadvantage, mainly related to ergot preparations, is the relatively high incidence of side-effects such as nausea, vomiting and increase in blood pressure
  • misoprostol may prevent severe postpartum haemorrhage but the evidence is inconsistent
    • misoprostol or intramuscular postaglandins are not more effective than conventional injectable uterotonics - both lead to more adverse effects
    • the review concludes that neither intramuscular prostaglandins nor misoprostol are preferable to conventional injectable uterotonics as part of the management of the third stage of labour especially for low-risk women.

Reference:

  1. NICE (September 2007). Intrapartum care.
  2. Gulmezoglu AM et al. Prostaglandins for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD00049
  3. NICE (April 2021). Postnatal care

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.